Arecor’s H121 results reiterate the stellar progress achieved, both developmentally and operationally, during the six months to June 2021 and post-period. The H121 highlight was the successful AIM IPO in June, raising £20.0m (gross). The £22.1m cash balance at end-June 2021, together with expected licensing opportunities and milestones, provides an ample runway to achieve multiple value inflection points.
23 Sep 2021
H121 results underline quality of management execution
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
H121 results underline quality of management execution
Arecor Therapeutics PLC (AREC:LON) | 136 0 0.0% | Mkt Cap: 41.8m
- Published:
23 Sep 2021 -
Author:
Franc Gregori | Lala Gregorek -
Pages:
2
Arecor’s H121 results reiterate the stellar progress achieved, both developmentally and operationally, during the six months to June 2021 and post-period. The H121 highlight was the successful AIM IPO in June, raising £20.0m (gross). The £22.1m cash balance at end-June 2021, together with expected licensing opportunities and milestones, provides an ample runway to achieve multiple value inflection points.